TESARO (NASDAQ:TSRO) is up 58% premarket on modest volume in response to the news that it will be acquired by GlaxoSmithKline (GSK) for $75/share in cash, valuing the company at $5.1B.
Recommended For You
Comments (56)
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.